Evidence map›Paper›PMID 27061268›Full record

ArticleBiomaterials2016

Differential regulation of angiogenesis using degradable VEGF-binding microspheres.

David G Belair, Michael J Miller, Shoujian Wang, Soesiawati R Darjatmoko, Bernard Y K Binder, Nader Sheibani, William L Murphy

Open access · greenAbstract read
In one paragraph

Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 30 citations in OpenAlex.

  1. Biofabrication and Characterization of Vascularizing PEG-Norbornene Microgels.Journal of biomedical materials research. Part A · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Antiangiogenic activity of PLGA-Lupeol implants for potential intravitreal applications.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2017
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

David G BelairDepartment of Biomedical Engineering, University of Wisconsin-Madison, USA.
Michael J MillerDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, USA.
Shoujian WangDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, USA.
Soesiawati R DarjatmokoDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, USA.
Bernard Y K BinderDepartment of Surgery, University of Wisconsin-Madison, USA.
Nader SheibaniDepartment of Biomedical Engineering, University of Wisconsin-Madison, USA; Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, USA.
William L MurphyDepartment of Biomedical Engineering, University of Wisconsin-Madison, USA; Material Science Program, University of Wisconsin-Madison, USA; Department of Orthopedics and Rehabilitation, University of Wisconsin-Madison, USA. Electronic address: wlmurphy@wisc.edu.
University of Wisconsin–Madison · US

Funding

UW Vision Research Core - Administrative CoreP30EY016665 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI AKIHIRO IKEDA · 2005 to 2026
$12.6M
Training Program in Translational Cardiovascular Science (TPTCS)T32HL007936 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Lee Lochbaum Eckhardt, Gail A Robertson · 2001 to 2026
$11.6M
Novel Antiangiogenic Peptides for Treatment of Exudative AMDR24EY022883 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI SHEIBANI, NADER · 2013 to 2017
$6.2M
Biomaterials for local regulation of growth factor signalingR01HL093282 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI MURPHY, WILLIAM L. · 2009 to 2018
$3.3M
Vascular Surgery Research Training ProgramT32HL110853 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI MATSUMURA, JON STEVEN · 2012 to 2021
$2.6M
Probing biochemical/biophysical influences on endothelial-mesenchymal transitionR21EB016381 · NIBIB · UNIVERSITY OF WISCONSIN-MADISON · PI MURPHY, WILLIAM L., SCHWARTZ, MICHAEL PAUL · 2013 to 2014
$399k
NEI NIH HHS P30 EY016665NEI NIH HHS R24 EY022883NHLBI NIH HHS R01 HL093282NHLBI NIH HHS T32 HL007936NHLBI NIH HHS T32 HL110853NIBIB NIH HHS R21 EB016381
6 · The paper itself

Abstract

Vascular endothelial growth factor (VEGF) spatial and temporal activity must be tightly controlled during angiogenesis to form perfusable vasculature in a healing wound. The native extracellular matrix (ECM) regulates growth factor activity locally via sequestering, and researchers have used ECM-mimicking approaches to regulate the activity of VEGF in cell culture and in vivo. However, the impact of dynamic, affinity-mediated growth factor sequestering has not been explored in detail with biomaterials. Here, we sought to modulate VEGF activity dynamically over time using poly(ethylene glycol) microspheres containing VEGF-binding peptides (VBPs) and exhibiting varying degradation rates. The degradation rate of VBP microspheres conferred a differential ability to up- or down-regulate VEGF activity in culture with primary human endothelial cells. VBP microspheres with fast-degrading crosslinks reduced VEGF activity and signaling, while VBP microspheres with no inherent degradability sequestered and promoted VEGF activity in culture with endothelial cells. VBP microspheres with degradable crosslinks significantly reduced neovascularization in vivo, but neither non-degradable VBP microspheres nor bolus delivery of soluble VBP reduced neovascularization. The covalent incorporation of VBP to degradable microspheres was required to reduce neovascularization in a mouse model of choroidal neovascularization in vivo, which demonstrates a potential clinical application of degradable VBP microspheres to reduce pathological angiogenesis. The results herein highlight the ability to modulate the activity of a sequestered growth factor by changing the crosslinker identity within PEG hydrogel microspheres. The insights gained here may instruct the design and translation of affinity-based growth factor sequestering biomaterials for regenerative medicine applications.

Indexed as

MicrospheresNeovascularization, PhysiologicAnimalsChoroidal NeovascularizationCross-Linking ReagentsDisease Models, AnimalHumansHuman Umbilical Vein Endothelial CellsHydrogel, Polyethylene Glycol DimethacrylateInduced Pluripotent Stem CellsMice, Inbred C57BLPeptidesPolyethylene GlycolsSignal TransductionVascular Endothelial Growth Factor ACross-Linking ReagentsHydrogel, Polyethylene Glycol DimethacrylatePeptidesPolyethylene GlycolsVascular Endothelial Growth Factor ABiomimetic microspheresChoroidal neovascularizationDegradable biomaterialsEndothelial cellsGrowth factor sequesteringVascular endothelial growth factor

Identifiers

PMID27061268
PMCPMC4866489
OpenAlexW2300474316

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.